Posted by Michael Wonder on 16 Apr 2025
Leqembi (lecanemab) is the first medicine that slows progression of early Alzheimer’s disease to be authorised in the European Union
15 Apil 2025 - Eisai and Biogen announced today that the European Commission has granted the amyloid-beta monoclonal antibody Leqembi (lecanemab) marketing authorisation in the EU.
This makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease to be granted a marketing authorisation in the EU.
